Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

MMJ Recs

MAY 9, 2024

Many veterans struggle with various physical and psychological conditions resulting from their service. These professionals can provide valuable insights into whether medical cannabis is a suitable option based on the veteran’s medical history, current conditions, and treatment goals.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Veriheal

AUGUST 28, 2023

This discovery adds to the ongoing research on the medical use of psychedelics in psychiatry. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. In some cases, these patients are prone to depression and suicide. cm fine sawdust.”

Treatment 63

Treatment Clinical Trials Therapy Research and Development 63

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. . – December 16, 2021) – Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 19, 2021

“These patent filings are critical components of PsyBio’s corporate development strategy. “These patent filings are critical components of PsyBio’s corporate development strategy. PsyBio remains interested in developing the intellectual property landscape within the psycho-targeted development drug arena.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Additionally, they may help slow the growth of certain types of cancer cells, though further research is needed.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. The full statement. Nair, Ph.D., Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. The efficacy of such products has not been confirmed by approved research.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105

The Cannigma

FEBRUARY 2, 2021

Of these consumers, over half said the drug had a beneficial clinical effect on their condition. In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

PrestoDoctor

OCTOBER 11, 2023

One area of research that has been gaining attention is the use of CBD-rich cannabis in treating the social symptoms of Autism Spectrum Disorder (ASD). In this post, we will explore the benefits of CBD-rich cannabis for treating ASD, the science behind it, and how it can help break barriers for individuals with this condition.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 19, 2022

During his 24 years in Congress, Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility. About IGC: India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JULY 7, 2021

MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? BioMAP Diversity PLUS informs a drug candidate’s potency, selectivity, safety, mechanism of action and disease indication. Chief Scientific Officer for MyMD.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

The Cannigma

DECEMBER 12, 2022

Now, psychedelic research is booming. And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.

Law 105

Law Therapy Clinical Trials Research and Development 105

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

More than half the states in the country have now legalized medical cannabis for patients with qualifying conditions and several more have gone so far as to legalize recreational marijuana for adults. GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Lennox-Gestaut Syndrome.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. The report goes on to say it believes more research is needed into cannabis prescriptions in the U.K. But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. CBD Testers.co

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. NICE has made research recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy. They should also have a special interest in the condition being treated [ 5 ].

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

SEPTEMBER 24, 2019

Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55